Efficacy and safety of Qishen granules for chronic heart failure: A protocol for systematic review and meta-analysis

Abstract

Background: Qishen granules (QSG) is a famous traditional Chinese Medicine (TCM) formula used to treat chronic heart failure (CHF). The objective of this protocol is to clarify the efficacy and safety of QSG for treating CHF. Methods: Six databases will be electronically searched up to November 1, 2020 for randomized controlled trials (RCTs) in English and Chinese languages. Two independent reviewers will complete tasks of literature retrieval and data extraction. After that, the Cochrane Collaboration risk of bias tool will be utilized to assess methodological quality. The primary outcomes are left ventricular ejection fraction, left ventricular fractional shortening, and N-terminal B-type natriuretic peptide. The secondary outcomes consist of composite cardiac events, adverse effects, and quality of life. Meta-analysis will be performed using the Revman version 5.3. Results: This study will provide a high-quality synthesis of current evidence of QSG for CHF from primary and secondary outcomes. Conclusion: This study will provide evidence for the effectiveness and safety of QSG in the treatment of CHF. PROSPERO registration number: CRD42020150442. Abbreviations: CBM = Chinese Biomedical Literature Database, CHF = chronic heart failure, CNKI = Chinese National Knowledge Infrastructure, QSG = Qishen granules, QSKL = Qishen Keli, QSYQ = Qishen Yiqi, RCTs = randomized controlled trials, TCM = traditional Chinese Medicine, YXJD = Yixin Jiedu.